Elekta to Highlight New MOSAIQ OIS Functionality at ASCO Annual Meeting

Elekta’s latest release (v2.5) of MOSAIQ Oncology Information System (OIS) includes functionality specifically designed for medical oncology practices. At the American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-3, at McCormick Place in Chicago, Elekta (booth #4019) will reinforce the enduring reputation of MOSAIQ as the definitive, comprehensive and scalable OIS that is suitable for all types of cancer practices.

Chicago, IL United States — Friday, May 31, 2013

MOSAIQ 2.5, the latest release of Elekta’s market-leading oncology information system (OIS), provides a complete radiation oncology and medical oncology solution in a single patient record, accessible from all locations and throughout the entire care continuum.

The new functionality in MOSAIQ 2.5 will extend its support for comprehensive oncology centers that want a single, centralized treatment management solution capable of coordinating chemotherapy management, in addition to conventional RT treatments and more dynamic, adaptive therapies.
The tighter integration of planning and image management within MOSAIQ – along with customizable and automated workflow tools to configure MOSAIQ to match individual practice’s specific workflow needs – enhances efficiency and improves patient care. MOSAIQ also features unmatched connectivity to a wide array of hospital systems, lab systems and treatment devices.
ASCO reprises popular EHR Vendor Lab
For the seventh consecutive year, Elekta has been selected to demonstrate at ASCO’s EHR Vendor Lab. The 2013 Lab will be a live, in-person resource held June 1-3 in the Oncology Professionals Hall. The EHR Lab allows ASCO meeting attendees to gain hands-on experience with the latest EHR technology. This year, vendors will demonstrate key EHR functionality, such as clinical decision support and generation of disease-specific treatment plan.
“We’re proud to be showcasing the latest version of MOSAIQ in front of this global medical oncology audience,” says Todd Powell, Executive Vice President, Elekta Software. “We’ve listened carefully to our customers’ priorities, and we continue to develop features that make a difference for providers, practices and patients alike. We look forward to sharing the latest features in our booth and in the EHR Vendor Lab.”
MOSAIQ was the first comprehensive, oncology-specific EMR certified for meaningful use under the federal government’s American Recovery and Reinvestment Act. MOSAIQ v2.3 and higher is optimized for practices planning to demonstrate meaningful use under the 2011 edition, which qualifies them to receive payments from the Centers for Medicare & Medicaid Services (CMS) under Medicare rules.
Learn more about MOSAIQ at www.elekta.com/MOSAIQ.  


About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

Press Releases

For further information, please contact

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451
Email: johan.andersson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447
Email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time